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Five steps in the management 
of high blood pressure 
Dr Saviour CILIA 
Check up for high blood pressure (HBP) is one of the most common encounters in general 
practice. The prevalence ofhypertension increases with advancing age to the point where over 
half of the people 60-69 year of age and about three10urths of those over 70 years of age are 
affected. The primary goal of treating patients with HBP is to prevent complications and reduce 
the long-term total risk of cardiovascular morbidity and mortality. This requires treatment of all 
the reversible risk factors identified (smoking, dyslipidaemia or diabetes) and the appropriate 
management of associated clinical conditions, besides treatment of the raised BP per se. 
During the last few years numerous international guidelines 
on the management of hypertension have been proposed in an 
effort to improve our approach in managing HBP [1-6]. But these 
guidelines do not agree amongst themselves as they cater for 
different populations and give different importance to different 
studies. This article is an attempt to look at these guidelines and 
try to adapt them to the local scene in five simple steps. 
5tep 1: Blood Pressure Measurement 
Historically more emphasis has been placed on diastolic (DBP) 
than systolic blood pressure (SBP) as a predictor of cerebrovascular 
and cardiovascular disease. Nevertheless, observational studies 
[7,8] confirm a direct and independent relationship between SBP 
and DBP and risk of end organ damage. Of importance is the fact 
that SBP rises throughout the adult age range whereas DBP peaks 
at about age 60 years in men and 70 years in women, and falls 
gradually thereafter [9, l 0]. This fact identifies elderly patients with 
isolated systolic hypertension as being at particularly high risk. 
Thus, contrary to what was previously thought, SBP is considered 
by many to be a better predicator than DBP of cardiovascular 
disease. In practice, both SBP and DBP should continue to be 
used for the purposes of definition and classification (Tables land 
2) , risk assessment, and guidance of treatment thresholds of 
hypertension (Table 4). 
BP is characterized by large variations both within and between 
days. Therefore, the diagnosis of hypertension should be based 
on rnultiple BP measurements, taken on separate occasions. IfBP 
is only slightly elevated, repeated measurements should be 
obtained over several months. If a patient has a more marked BP 
elevation, evidence of hypertension-related organ damage or a 
high cardiovascular risk profile, repeated measurements should 
be obtained over shorter periods of time, such as weeks or days. 
BP can be measured by the doctor or by the nurse in the 
clinic, by the patient at home, or automatically over a 24 
hour period. 
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Category Systolic Diastolic 
Optimal <120 <80 
Nonnal 120-129 80-84 
High nonnal 130-139 85-89 
Mild hyperrension Grade l 140-159 90-99 
Moderate hyperrension Grade 2 160-179 100-109 
Severe hypenension Grade 3 .2: 180 .2: 110 
Isolated systolic hyperrension .2. 140 .2. 90 
Table l: WHO/ESH Classification of BP levels (mmHg) 
Clinic BP measurements 
BP can be measured by a mercury sphygmomanometer or 
other non-invasive devices (auscultatory, oscillometric or aneroid 
devices) When measuring Bp, care should be taken to: 
• Allow the patients to sit for several minutes in a quiet room. 
• Take two measurements spaced by 1-2 min. 
• Use a standard cuff (12-13 cm wide and 35 cm long) but 
have a larger and a smaller cuff available for fat and thin arms, 
respectively. 
• Have the cuff at the heart level, whatever the position of the 
patient. 
• Use phase I and V (disappearance) Korotkoff sounds to 
identify SBP and DBP respectively. 
• Measure BP in both arms at first visit; take the higher value 
as the reference one. 
• Measure BP l and 5 min after assumption of the standing 
position in the elderly and diabetic patients, for orthostatic 
hypotension. 
• Measure pulse rate for 30 seconds after the second 
measurement in the sitting position. 
• Clinicians should avoid unnecessarily frequent BP check to 
worried well patients as these give false reassurance (Box 1) 
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Home BP measurements 
Self-measurements of BP at home can provide information 
on BP on different days in settings as close to daily life conditions 
as possible. These values have been shown to have no white-
coat effect and to be more predictive of the presence and 
progression of organ damage than are clinic values [11]. Therefore, 
home BP measurements for suitable periods before and during 
treatment can also be recommended because this relatively cheap 
procedure may improve patient's adherence to treatment 
[121.Care should be taken to: 
• Advise only the use of validated devices (wrist devices are 
not validated) and semi-automatic rather than mercury 
sphygmomanometric devices should be recommended; 
• 1nstruct the patients to make measurement seated after several 
minutes of rest, and inform them of spontaneous BP 
variability; 
• Avoid excessive number of measurements and ensure that 
some are made before drugs are taken to provide information 
on duration of the treatment effect; 
• Note that normalityvalues are lower for home compared with 
clinic pressures (Table 2); 
• 1nstruct patients to keep proper record of the measured values 
and to avoid self-alterations of the treatment. 
Ambulatory BP measurements 
Several devices are available which permit the automatic 
monitoring of BP in patients allowed to conduct a near normal 
life. 1t has been shown that ambulatory BP correlates with 
hypertensive target organ damage and predicts the cardiovascular 
risk more closely than clinic BP [13,14]. Ambulatory BP is usually 
several mmHg lower than clinic BP CTable 2). 
24-hour ambulatory BP monitoring may be considered of 
additional clinical value, but the technique and its cost may limit 
its use in routine BP check. 
Step 2: Assessment for Risk factors 
Diagnostic procedures are aimed at identifying secondary 
causes of hypertension and evaluating the overall cardiovascular 
SBPjDBP Recommended 
(mmHg) follow-up* 
Optima1 BP <120 1 <80 1-2 years 
Normal BP 120-129/80-89 6-12months 
MildHI 140-159/90-99 1-3months 
Moderate HI 160-179/100-109 1-4 weeks 
Severe HI ~180 1 ~ 110 Immediate treatment 
BP treated & controlled 120-140 / 80-90 3-6 months* 
• Modify the scheduling of follow-up according to past BP measurements, 
cardiavascular risll factars, target argan isease, or concomitant conditions 
Box 1: Recommendations for follow-up BP check 
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risk by searching for risk factors , target organ damage and 
accompanying clinical conditions. The diagnostic procedures 
comprise medical history, BP measurements, physical examination 
and investigations. 
Guidelines for family and clinical history 
A comprehensive family history should be obtained, with 
particular attention to hypenension, dyslipidaemia, diabetes , 
coronary heart disease, stroke, or renal disease. 
l. Duration and previous level of HBP 
2. Indications of secondary hypertension: 
(a) family history of renal disease (polycystic kidney) 
(b) renal disease, urinary tract infection, haematuria, analgesic 
abuse (parenchymal renal disease) 
(c) drug!substance intake: oral contraceptives, liquorice, 
carbenoxolone, nasal drops, cocaine, steroids, non-steroidal 
anti-inflammatory drugs, amphetamines, erythropoietin, 
cyclosporin 
(d) episodes of sweating, headache, anxiety, palpitation 
(phaeochromocytoma) 
(e) episodes of muscle weakness and tetany (aldosteronism) 
3. Risk factors: 
(a) family and personal history of hypertension and 
cardiovascular disease 
(b) family and personal history of hyperlipidaemia 
(c) family and personal history of diabetes mellitus 
(d) smoking habits 
(e) dietary habits 
co obesity; and amount of physical exercise 
(g) personality 
4. Symptoms of organ damage: 
(a) brain and eyes: headache, vertigo, impaired vision, transient 
ischaemic attacks, sensory or motor deficit 
(b) heart: palpitation, chest pain, shortness of breath, 
swollen ankle 
(c) kidney: thirst, polyuria, nocturia, haematuria 
(d) peripheral arteries: cold extremities,intermittent claudication 
SBP 
Clinic BP 140 
- ----~---
Home (seW BP 135 
High normal 130-139 
24-hr ambulatory BP 125 
Table 2: BP thresholds (mmHg) for definition ofhypertension 
with different types of measurement 
DBP 
90 
85 
85-89 
80 
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5. Previous antihypertensive therapy: 
drugs used, efficacy and adverse effects 
6. Personal, family, and environmental factors 
Guideline for physical examination 
In addition to BP measurement, physical examination 
should search for evidence of additional risk factors (in particular 
abdominal obesity) , for signs suggesting secondary 
hypertension, and for evidence of organ damage. 
1. Signs of secondary hypertension and organ damage: 
(a) Features of Cushing syndrome. 
(b) Skin stigmata of neurofibromatosis 
(phaeochromocytoma) . 
(c) Palpation of enlarged kidneys (polycystic kidney). 
(d) Auscultation of abdominal murmurs (renovascular 
hypertension) . 
(e) Auscultation of precordial or chest murmurs (aortic 
coarctation or aortic disease). 
(D Diminished and delayed femoral and reduced femoral 
BP (aortic coarctation, aortic disease). 
2. Signs of organ damage: 
(a) Brain: murmurs over neck arteries, motor or sensory 
defects. 
(b) Retina: fundoscopic abnormalities. 
(c) Heart: location and characteristics of apical impulse, 
abnormal cardiac rhythms, ventricular gallop, pulmonary 
rales, dependent oedema. 
(d) Peripheral arteries: absence or reduction of pulses cold 
extremities, ischaemic skin lesions. 
Guidelines for laboratory investigations 
Laboratory investigations are directed at providing evidence 
of additional risk factors, searching for secondary hypertension 
and assessing absence or presence of target organ damage. The 
minimum laboratory investigations needed are a matter of 
debate. However, it is agreed that investigations should progress 
from the most simple to the more complicated. 
Risk factors Nonnal BP High Nonnal BP 
and disease SBP 120-129 SBP 130-139 
history or DBP 80-84 or DBP 85-89 
No risk factors Average risk Average risk 
1-2 risk factors Low added risk Low added risk 
~ 3 risk factors, 
TOD orDM Moderate added risk High added risk 
.ACC High added risk Very high added risk 
Major risk factors 
• Levels of systolie and diastolie BP 
• Men> 55 years 
• Women>65 years 
• Smoking 
• Dyslipidaemia(total eholesteroL 6.5 mmol!l, or LDL-cholesteroL 
4.0 mmol!l, or HDL-eholesterol M , 1.0,w, 1.2 mmol!l) 
• Family history of premature CVD(at age , 55 years M, 65 years W) 
• Abdominal obesity(eireumferenee M> 102 em, W>88 em) 
Thrget organ damage (TOD) 
• Left vemricular hypemophy 
• Ultrasound evidenee of arterial wall thickening or atherosclerotie plaque 
• Slight inerease in serum ereatinine (M 115-133,W 107-124 umol!l); 
• Mieroalbuminuria(30-300mg12 4h; albumin-ereatinine ratio M > 22, 
W >31 mglg; M> 2.5,w > 3.5 mglmmoD 
Diabetes Mellitus 
Fasting plasma glueose ~7.0 mmol/! 
• Postprandial plasma glucose > 11.0 mmol!l 
Associated clinical conditions (ACC) 
• Cerebrovascular disease: ischaemic stroke; cerebral haemorrhage; transiem 
ischaemic anaek· Heart disease: myocardial infarction; angina; coronary 
revascularizatibn; congestive heart failure 
Renal disease: diabetic nephropathy; rena! impairrnem (serum creatinine 
M. > 133, Wl24 >molJl) proteinuria (> 300 mgl24 h) 
Peripheral vascular disease· Advaneed retinopathy: haemorrhages 
or exudates, papilloedema 
M, men; W, women; LDL, low-density lipoprotein; HDL, high-density lipoprotein 
Table 3: Factors injluencing prognosis 
1. Routine tests: 
(a) Fasting plasma glucose 
(b) Serum total cholesterol 
(c) Serum HDL-cholesterol 
(d) Fasting serum triglycerides 
Mild HT Moderate HT 
SBP 140-159 SBP 160-179 
or DBP 90-99 or DBP 100-109 
Low added risk Moderate added risk 
Moderate added risk Moderate added risk 
High added risk Very high added risk 
Very high added risk Very high added risk 
-- --
Severe HT 
SBP > 180 
or DBP> 110 
High added risk 
Very high added risk 
Very high added risk 
Very high added risk 
ACC, associated clinical conditions; TOD, ta/get o/gan damage; HI, hypertension; DM, diabetes mellitlls 
Table 4: Stratification of risk to quantify prognosis 
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(e) Serum uric acid 
CD Serum creatinine 
(g) Serum potassium 
(h) Haemoglobin and haematocrit 
(i) U rinalysis 
G) Electrocardiogram 
2. Recommended tests: 
(a) Echocardiogram 
(b) Carotid (and femoral) ultrasound 
(c) C-reactive protein 
(d) Microalbuminuria (essential in diabetics) 
(e) Quantitative proteinuria (if dipstick positive) 
CD Fundoscopy (in severe hypertension) 
Step 3: Classification and Stratification 
The relationship between BP levels and risk of end organ 
damage is continuous and this makes any numerical definition 
and classification of hypertension arbitrary. The real threshold 
for treating hypertension must be a flexible one resulting from 
evidence of cardiovascular risk profile of each individual. The 
new guidelines introduced a new classification that includes high 
normal BP (ESH [3]) or prehypertension QNC 7 [2]) 
This new designation is intended to identify those individuals 
who would benefit from preventive measures such as lifestyle 
change or early intervention. 
On these bases , a classification using stratification for total 
cardiovascular risk (Table 4) was suggested in the WHO/lSH[4J 
and ESH/ESC[3J guidelines. The terms low, moderate, high and 
. very high added risk are calibrated to indicate an approximate 
absolute lO-year risk of cardiovascular disease of,l5%, 15-20%, 
Lifestyle change Reduction in SBP Other benefits 
Smoking cessation Not quantified The single most powerful 
lifestyle measure for the 
prevention of 
non-cardiovascular 
and cardiovascular diseases 
Weight reduction 5-20mmHgl lOkg lmprove associated risk 
factors such as insulin 
resistance, diabetes, 
hyperlipidaemia and left 
vennicular hypertrophy 
Regular 4- 9 mmHg Same as above 
physical activity 
Healthy eating plan 8-1 4mmHg Same as above 
Moderation of 2-4 mmHg Associated with a 
alcohol intake high risk of srroke 
particularly 50 
for binge drinking 
Reduction of 
dietary salt 2-8 mmHg 
Table 5 - Lifestyle modification and reduction in BP 
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20- 30% and> 30%, respectively, according to Framingham 
criteria [15J , or an approximate absolute risk of fatal cardiovascular 
disease<4%, 4-5%, 5-8%, and >8% according to the SCORE 
charr [16J. 
Step 4: Therapeutic Strategy 
Primary prevention and Lifestyle changes 
Primary prevention entails that all patients should be screened 
for HBP and increased cardiovascular risk. Whereas, patients with 
increased risk or on treatment should be encouraged to attend 
for regular check-ups, the worried well should be reassured and 
discouraged from doing frequent BP check-ups (Box 1). On the 
other hand, clinicians should take every opportunity not to miss 
those patients who attend clinic infrequently and are not aware 
of their BP and cardiovascular status. 
Adopting a healthy lifestyle by all persons is critical for the 
prevention of HBP and is an indispensable pan in the 
management of hyperrension. Each encounter for BP check-up 
should be an opporrunity to advise patients on healthy lifestyle. 
Lifestyle advice is appropriated for all patients with or without 
HBP or on antihypertensive therapy. The lifestyle measures that 
are widely agreed to lower BP and cardiovascular risk are indicated 
in Table 5. 
Secondary prevention and 
medical intervention 
Guidelines for initiating antihypertensive treatment are based 
on two criteria: the level of SBP and DEP (Tables l and 2) and 
the total level of cardiovascular risk (Table 4) The total level of 
cardiovascular risk has become a more important indicator than 
(Adapted from ESH/ESC guid1ines) 
(Untreated High BP) 
l l 
Combined agent 
atlowdose 
BP goal nct achieved 
3- OnJgcombination 
at effective dose 
Figure 1: Monotherapy or combillation therapy 
Maltese Family Doctor !t-Tabib tal-FamiUa 
Hlgh lOrmalBP Mlld/Moderate HT I Severe HT , t + 
Assess risk factors, Assess risk factors, Beg in treatment 
TOD,DM, ACC TOD,DM,ACC im mediate Iy 
l . .1 . .1 ... . . 
Lifestyle modification & Lifestyle modification & correct 
, 
Assess risk factors, 
correct oth er risk factors other risk factors or disease ! TOD, DM,ACC 
~- . -
i * ~ c:: --~- :==:J Lifestyle modification & 
~tratlfY absolute risk JI stratify absolute risk correet risk factors 
Il I :::t + = + f f f . = := - . 
V.High High Moderate Low V.High High Moderate low 
.. + .. .. t .. .. .. 
.. -.' -
Monitor Monitor Begin Begin Monitor Monitor Begin Begin 
Rx Rx BP BP Rx Rx ' BP & BP & 
... ,.' . - -. ~- - ...... -
-
.. 
SBP~140 
: DBP~90 
Begin 
Rx 
Box 2: Recommended T1Ierapeutic Strategy 
the BP level for intervention. Box 2 includes recommendations 
about initiation of treatment in patients with all grades of 
hypertension. 
The evidence of BP lowering benefits in patients with high 
normal BP is so far limited to subjects with stroke, coronary artery 
disease and diabetes. Antihypertensive treatment within high 
normal BP range can only be recommended for patients who are 
at least at high risk Close monitoring of BP is recommended for 
patients at low or moderate risk, who are considered to benefit 
mostly from lifestyle modification measures and correction of 
other risk factors. 
Risk Factors Risk Factors 
... I 
.. .. + 
SBP<140 SBP140-,159 OBP<140 
DBP<90 DBP90-99 OBP< 90 
Continue Consider Continue 
Monitoring Rx monitorinġ 
10intice1 
fH*)CICAIfW IAT~1 
a-bloclc.. 1.,=t.1 
Possible combination of different classes of antihyperiensive 
agents. The most rational combinations are represented as thick 
lines. ACE, angiotensin-converting enzyme. The frames indicate 
classes of antihypertensive agents proven to be beneficial in 
controlled intervensional trials. 
In patients with mild to moderate hypenension, it is 
recommended to check BP values on several occasions, initiate 
lifestyle measures and stratify absolute risk Antihypertensive drug 
treatment should be initiated promptly in subjects classified as 
at high orvery high risk, whereas in subjects at moderate or low 
added risk Bp, as well as other cardiovascular risk factors, should 
be monitored for extended periods Cat least 3 months) with only 
non-pharmacological treatment lf after extended observation, Figure 2: Drug Combinations (Adapted from ESH/ESC guidlines) 
I 
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Class 
Diuretics (thiazidesl 
Diuretics (loopl 
Diuretics (anti-aldosteronel 
Beta-Blockers 
Calcium a~tagonists 
(dihydropyridinesl 
Calcium antagonists 
(verapamil, diltiazeriJ.l 
Angiotensin-converting 
enzyme (ACEl inhibitors 
Angiotensin II 
receptorantagonists 
(ATl-blockersl 
Indications 
Congestive hean failure; 
elderly hypenensives; 
isolated systolic hypenension; 
hypenensives of African origin 
Renal insufficiency; 
congestive hean failure 
Congestive hean failure; 
post-myocardial infarction 
Angina pectoris; 
post-myocardial infarction; 
congestive hean failure (up-titrationl; 
pregnancy; 
tachyarrhythmias 
Elderly patients; 
isolated systolic hypenension; 
angina pectoris; 
peripheral vascular disease; 
carotid atherosclerosis; 
pregnancy 
Angina pectoris; 
carotid atherosclerosis; 
supraventricular rachycardia 
Congestive heart failure; 
LV dysfunction; 
post-myocardial infarction; 
non-diabetic nepħropatħy; 
type l diabetic nephropathy; 
proteinuria 
Type 2 diabetic nephropathy; 
diabetic microalbuminuria; 
proteinuria; 
left ventricular hypertrophy; 
ACE-inhibitor cough 
-------------------Alpha-Blockers Prostatic hyperplasia (BPH); 
hyperlipidaemia 
Compelling Contraindications 
Gout 
Renal failure; 
hyperkalaemia 
Asthma; 
chronic obstrllctive 
pulmonary disease; 
A-V block grade 2 or 3 
A-V block grade 2 or 3; 
congestive heart failure 
Pregnancy; 
hyperkalaemia; 
bilateral renal artery stenosis 
Pregnancy; 
hyperkalaemia; 
bilateral renal anery stenosis 
Onhostatic hypotension 
Possible Contraindications 
Pregnancy 
Peripheral vascular disease; 
glucose intolerance; 
athletes and physically 
active patients 
Tachyarrhythmias; 
congestive heart failure 
Congestive heart failure 
Table 6: Indications and contraindications for the major dasses of antihypertensive drugs 
systolic values > 140 or diastolic values > 90 mmHg persist, 
antihypertensive drug treatment should be initiated in patients 
with moderate risk, and considered in patients with lower risk. 
In patients with severe hypertension, the elevated BP values 
should be checked within a few days and treatment instituted 
quickly, without the preliminary need of establishing the absolute 
risk. Complete assessment of other risk factors, target organ 
dam~ge, or associated disease can be carried out after treatment 
has been started, and lifestyle measures can be recommended at 
the same time as initiation of drug therapy. 
o 
classes of antihypertensive agents (fig 2) are equally suitable for 
first-line therapy as monotherapy or combination therapy, 
provided that there are no associated complications. There is 
also evidence that specific drug classes may differ in some effect, 
or in special groups of patients. When there is evidence of 
increased cardiovascular risk profile, target organ damage, clinical 
cardiovascular or renal disease or diabetes then, specific 
antihypertensive drugs with compelling indications (based on 
clinical tria!) should be used (Table 6) Long-acting drugs or 
preparations providing 24-h efficacy on a once daily basis are 
generally preferred as they offer better BP control. 
5tep 5: Choice of antihypertensive drugs Within the array of available evidence, the choice of drugs 
The main benefits of antihypertensive therapy are due to will be influenced by many factors, including: 
lowering of blood pressure per se and all the standard major • previous experience of the patient with the agents; 
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es .... [Offer CV care) 
yes +{ Offer diabetic care) 
+ 
Measure8P on 2 fUr1h er Qccasions~ 
.. 
;~YR~rt~ris' 9,;9': 
l 
+yes 
~ [ Refer to HT specialist] 
Rev.iew 
itt 1-2yrs 
no 
yes 
R'eVlevi :. 
·m 3~€i mtħ:s 
Figure 3: Management jlow chart 
.. 
(Adapted from North ofEngland hypertention guidelines dcvelopment group) 
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• cost of drugs; 
• patient's preference; 
• clinical indications 
Monotherapy versus combination therapy 
In most, if not all, hypertensive patients, therapy should be 
started gradually, and target BP values achieved progressively 
through several weeks. To reach target Bp, it is likely that a large 
proportion of patients will require combination therapy with 2 
or 3 agents. In mild hypertensives, monotherapy is likely to be 
successful more frequently. On the other hand, patients with 
moderate to severe hypertension or with concomitant disease, 
such as diabetes , are more likely to be controlled with 
combination therapy. According to the baseline BP and the 
presence or absence of complications, it appears reasonable to 
initiate therapy either with a low dose of a single agent or with 
a low-dose combination of two agents Cfigure 1). The advantage 
of starting with low dose monotherapy, is the ease to identify 
adverse effects and to find the drug to which any individual 
patient best responds. But the procedure is laborious and 
frustrating for both doctors and patients, and may lead to low 
compliance. An obvious disadvantage of initiating with two 
drugs is that of potentially exposing the patient to an 
unnecessary agent, but the advantages are that: 
l. by using two drugs with different mechanisms of action, it 
is more likely that blood pressure and its complications are 
controlled; 
2. by using combinations, both the first and second drugs can 
be given in the low dose range that is more likely to be free 
of side-effects; 
3. fixed low-dose combinations allowing the administration of 
two agents within a single tablet , thus optimizing 
compliance. 
Figure 2 shows the most commonly used drug combinations 
that were proved to be effective and tolerated by patients 
Conclusion 
It is now recognised that the management of hypertension 
must not be performed in isolation (Box 2, Fig 3). Full 
cardiovascular risk assessment of the patient is required. The 
patient should be considered holistically and all risk factors and 
associated clinical conditions must be assessed and managed. 
Despite major efforts to diagnose and to treat hypertension, 
this condition remains a leading cause of morbidity and 
mortality, and goal BP levels are seldom achieved. It is therefore 
highly desirable to improve this unsatisfactory delivery of care 
of such a common condition. 
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